(19)
(11) EP 2 175 834 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
22.08.2012 Bulletin 2012/34

(45) Mention of the grant of the patent:
23.02.2011 Bulletin 2011/08

(21) Application number: 08772467.0

(22) Date of filing: 09.07.2008
(51) International Patent Classification (IPC): 
A61K 9/08(2006.01)
A61K 38/26(2006.01)
 A61K 47/26(2006.01)
(86) International application number:
PCT/US2008/069473
(87) International publication number:
WO 2009/009562 (15.01.2009 Gazette 2009/03)

(54)

GLP-1-FC FUSION PROTEIN FORMULATION

GLP-1-FC FUSIONSPROTEIN-FORMULIERUNG

FORMULATION DE PROTÉINE DE FUSION GLP-1-FC

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
Designated Extension States:
AL BA MK RS

(30) Priority: 10.07.2007 US 948855 P

(43) Date of publication of application:
21.04.2010 Bulletin 2010/16

(73) Proprietor: ELI LILLY AND COMPANY
Indianapolis, IN 46285 (US)

(72) Inventor:
  • NG, Kingman
    Carmel, Indiana 46032 (US)

(74) Representative: Kent, Lindsey Ruth et al
Eli Lilly and Company Limited Lilly Research Center European Patent Operations Sunninghill Road
Earl Wood Manor Windlesham Surrey GU20 6PH
Earl Wood Manor Windlesham Surrey GU20 6PH (GB)


(56) References cited: : 
WO-A-2006/068910
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).